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INTRODUCTION
Positive airway pressure (PAP) is the most effective treatment for
patients with moderate-to-severe obstructive sleep apnea (OSA)
(1). However, compliance with continuous positive airway pres-
sure (CPAP) treatment is suboptimal because of patient discom-
fort and various complications (2). Many investigators have sought
methods by which PAP use might be enhanced (3).
In contrast to the fixed pressure level used in conventional
CPAP therapy, autoadjusting positive airway pressure (APAP)
devices adjust air pressure within a predetermined range accord-
ing to patient need, thereby delivering the lowest effective pres-
sure during the night.
Flexible PAP (using expiratory pressure relief [EPR], ResMed
Inc., Sydney, Australia) is a recent variant of PAP developed to
improve patient comfort and increase duration of use by lower-
ing the pressure below the prescribed PAP in early exhalation
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Original Articlewith a return to the prescribed level at the end of expiration (4, 5).
No study has addressed the compliance of patients who have
opportunities to select preferred PAP modalities. We introduced
APAP, CPAP, and EPR to OSA patients during a trial period
and allowed them to choose and purchase their preferred instru-
ment. The aims of the study were to discover such preferences,
to explore compliance, and to determine factors influencing com-
pliance.
MATERIALS AND METHODS
Materials
Sixty-nine patients (62 males and 7 females), who complained
of snoring, sleep apnea, or excessive daytime sleepiness, were
recruited from the Asan Medical Center Snoring and Sleep Apnea
Clinic between December 2006 and November 2007. All patients
were diagnosed with OSA based on full polysomnography and
all patients tested therapeutic PAP. Mean patient age was 46.1
yr (range 23 to 67 yr). 
Full polysomnography was performed from 10 pm on the day
of admission to 6 am on the following morning in a neurology
center. Procedures included electroencephalography (C3/A1,
C4/A2, O1/A1, O2/A2); electro-oculography; electromyogra-
phy of the chin and the anterior tibialis; electrocardiography;
respiratory flow measurement (using a nasal cannula/pressure
transducer); measurement of thoracic or abdominal movements
(inductive plethysmography); and arterial oxygen saturation
measurement (pulse oximetry). Apnea was defined as cessation
of airflow for at least 10 sec and hypopnea was defined as blood
oxygen desaturation of 4% or greater and 30% reduction in air-
flow for more than 10 sec. The apnea-hypopnea index (AHI) was
the number of apneas and hypopneas per hour of sleep.
OSA was diagnosed when a patient had an AHI greater than
5 and symptoms of excessive daytime sleepiness, or an AHI gr-
eater than 15 regardless of daytime symptoms, in line with the
2007 American Academy of Sleep Medicine recommendations.
Severity of OSA was judged from AHI data, and graded as mild
OSA (5≤AHI<15/hr), moderate OSA (15≤AHI<30/hr), and
severe OSA (AHI>30/hr). When we decided to use PAP thera-
py, optimal fixed pressures for PAP were determined by manu-
al titration during the second night in the clinic. 
Study design (Fig. 1)
Patients considering PAP therapy tested a device (ResMed Inc.)
for 1 month. After an adaptation period of 1 week, they exper-
imented with APAP (S8 AutoSet Spirit
TM), CPAP (S8 Elite
TM),
and EPR (S8 Elite
TM, EPR) at least once every week. In choosing
their preferred form of PAP therapy after the 1-month trial peri-
od, patients purchased instruments after consideration of usage
information recorded by the test device software, and also con-
sidered convenience of use. Those who experienced no difference
between APAP and CPAP were recommended to purchase a
CPAP-mode instrument. Patients with congestive heart failure,
patients with chronic obstructive pulmonary disease, those expe-
cted to have nocturnal arterial desaturation arising from condi-
tions other than OSA (such as obesity hypoventilation syndrome),
patients who did not snore (either naturally or as a result of palate
surgery), and patients who showed central sleep apnea syndro-
mes, were not candidates for APAP.
Patients were considered as a group, and we obtained data on
body mass index (BMI, kg/m
2); neck circumflex (cm); palatine
tonsil size; palate position according to Friedman’s classification;
hypertension defined as systolic blood pressure (BP) >140 mm
Hg or diastolic BP>90 mm Hg in three independent measure-
ments using a conventional sphygmomanometer (6); alcohol
intake classified levels of it into none and alcohol drinker; scores
on the Epworth sleepiness scale (ESS), Pittsburgh Sleep Quality
Index (PSQI), Apnea Index (AI), AHI, apnea-arousal Index;
minimum SaO2 values (%); proportions of nonsupine-position
sleep time (nonsupine sleep time/total sleep time), position depen-
dence of sleep (nonsupine AHI/supine AHI); and dependence of
rapid eye movement (REM) sleep on AHI (REM AHI/non-REM
AHI).
Patients have visited our clinic every month since the trial peri-
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Fig. 1. Summary of the study protocol.
*Clinical assessment baseline characteristics (age, sex, body mass
index, neck circumflex, Friedman stage, hypertension status, alcohol
use, smoking, sleep study data, optimal pressure in treatment study,
Epworth Sleepiness Score, Pitt- sburgh Sleep Quality Index). 
APAP: autoadjusting positive airway pressure; CPAP: continuous posi-
tive airway pressure; EPR: expiratory pressure relief (flexible CPAP). od; we have assisted them to overcome any discomfort and we
collected data recorded in their devices. Results from patients who
used PAP for more than 3 months were analyzed using Autoscan
version 5.7
� software from ResMed Inc. The data monitoring
system recorded AHI, the pressure profile (95th percentiles of
pressure, median pressure, and maximal pressure), air leakage,
and device use time (when used, hours of daily use, and days
used per month). From these data, we calculated:
Mean daily use (hr)
=(total hr when CPAP used)/(total number of follow-up days)
Percentage of days CPAP was used 
=(number of days when ≥1 hr of use was recorded)/(total
number of follow-up days)
Percentage of days that PAP was used for >4 hr
=(number of days when >4 hr of use was recorded)/(total num-
ber of follow-up days)
Commonly used definitions of adequate compliance are PAP
usage of >4 hr per night for 70% of days (3) or more than 5 days
per week and for more than 4 hr per day of use (7). But other
reports presented compliance as the duration of nightly use of
the device (8), the amount of time that the device is switched on
and being worn correctly so as to deliver effective therapeutic
pressure (9) and percentage of days CPAP was used, mean daily
use (hr) and mean daily use on days CPAP was used (10). In
other words, because there is no standardized definition of CPAP
compliance, compliance was judged by mean daily use (hr), per-
centage of days on which PAP was used, and percentage of days
on which PAP was used for >4 hr.
The mean follow-up period was 8.4 months.
Statistical analysis
Numerical variables such as anthropometric and polysomnogr-
aphic data are expressed as means±SDs. Compliances accord-
ing to hypertension, alcohol intake, severity of AHI, and propor-
tion of nonsupine sleep time, were calculated using the Mann-
Whitney test. Calculations of significant differences between man-
ual titration pressure and auto-titration pressure according to PAP
mode, and assessment of compliance according to mode, were
made using the Kruskal-Wallis test. Correlation coefficients be-
tween compliance on the one hand, and BMI, neck circumflex,
Friedman’s classification, ESS score, PSQI score, AI score, AHI
score, apnea-arousal index scores, minimum SaO2 (%) values,
proportion of nonsupine sleep time, position dependence of sleep,
position dependence of REM sleep, AHI during PAP use, PAP
pressure, and air leakage during PAP, on the other, were calcu-
lated using the Pearson correlation test. To determine important
affecting factors of compliance with PAP, we used a stepwise mul-
tiple regression model to select out significant variables; only th-
ose variables that produced a P-value <0.05 were included in the
final model (P-values of <0.05 were considered statistically sig-
nificant). Data analyses were performed using SPSS for Windows,
ver. 15.0 (SPSS, Chicago, IL, USA).
RESULTS
Sixty-nine patients engaged in PAP therapy, including 3 (4.4%)
with mild OSA, 13 (18.8%) with moderate OSA, and 53 (76.8%)
with severe OSA.
Preference
Forty-one (59.4%) of the 69 patients purchased a device after
the 1-month trial; 28 patients (40.6%) dropped out. Of the 41
patients who purchased PAP devices, 16 (39%) chose APAP,
20 (48.8%) CPAP, and 5 (12.2%) EPR. Twenty-four patients
(34.7%), 11 of the 16 (68.8%) who purchased APAP devices;
10 of 20 (50.0%) who purchased CPAP instruments; and 3 of 5
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Device Purchase
41 (59.4%)
APAP
16/41 (39%)
APAP
11/16
(68.8%)
CPAP
10/20
(50.0%)
EPR
3/5
(60%)
CPAP
20/41 (48.8%)
Divice Adherence
above 3 months
24 (34.7%)
EPR
5/41 (12.2%)
Drop out
28 (40.6%)
Device Trial for 1 month (n=69)
Fig. 2. Compliance of patients. 
APAP: autoadjusting positive airway pressure; CPAP: continuous posi-
tive airway pressure; EPR: expiratory pressure relief (flexible CPAP).
Fig. 3. Difference between manual titration pressure and auto-titration
pressure according to PAP mode.
APAP: autoadjusting positive airway pressure; CPAP: continuous pos-
itive airway pressure; EPR: expiratory pressure relief (flexible CPAP).
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(60%) who purchased EPR devices, used PAP for more than 3
months (Fig. 2). 
When we analyzed differences between manual titration pres-
sure and auto-titration pressure according to PAP mode in 37
patients (so excluding 4 patients for whom fixed PAP pressures
were not available), no statistically significant difference was seen.
The means were -0.71±1.43 cm H2O in APAP users, -1.31±
1.31 cm H2O in CPAP patients, and -0.75±1.12 cm H2O in EPR
users (P=0.498) (Fig. 3).
Of the 24 long-term (at least 3 months) PAP users, 23 were
male and 1 was female, of mean age 45.4 yr. Three patients were
of stage II and 17 of stage III on Friedman’s classification (so ex-
cluding 4 patients for Friedman’s classification were not record-
ed). Thirteen had hypertension and 12 were consumers of alco-
hol. Table 1 shows other demographic and sleep variables.
Compliance according to hypertension status
Patients with hypertension showed a statistically significant high-
er percentage of PAP usage days than did normotensives (P=
0.003). The percentage of days on which PAP was used for >4 hr
was slightly higher in hypertensives than in normotensives but
this was not statistically significant (P=0.062) (Table 2).
Compliance according to alcohol consumption
The mean daily use (hr) (P=0.354), the percentage of days on
which PAP was used (P=0.413), and the percentage of days on
which PAP was used for >4 hr (P=0.477) did not differ with sta-
tistical significance between alcohol consumers and those who did
not drink alcohol.
Compliance according to severity of AHI
When 4 patients with moderate OSA (16.7% of total) and 20 pa-
tients with severe OSA (83.3%) were compared, the mean daily
use (hr) (P=0.337), percentage of days on which PAP was used
(P=0.681), and the percentage of days on which PAP was used
for >4 hr (P=0.140) showed no statistically significant differences.
Compliance according to PAP mode
When APAP, CPAP, and EPR data were compared, mean
daily use (hr) (P=0.572), percentage of days on which PAP was
used (P=0.560), and percentage of days on which PAP was used
for >4 hr (P=0.709), did not significantly differ (Table 3).
Compliance according to proportion of nonsupine sleep
time
There was an obvious negative correlation between nonsupine
sleep time as shown by standard polysomnography and percent-
age of days on which PAP was used (P=0.039, correlation coef-
ficient=-0.424) (Table 4).
Mean±SD
Table 1. Demographic and sleep variables in PAP users (n=24) 
Demographic variables
Age (yr) 45.4±10.7
BMI (kg/m
2) 26.5±3.4
Neck circumflex (cm) 42.4±3.4
ESS 11.6±5.5
PSQI 7.7±2.5
Sleep variables
AI 40.9±22.5
AHI 49.7±22.2
Nonsupine position sleep time/TST (%) 34.0±27.4
Nonsupine position AHI/supine position AHI (%) 33.0±33.2
REM sleep AHI/NREM sleep AHI (%) 67.5±56.2
Minimum SaO2 (%) 73.8±11.1
Apnea-arousal index 43.9±22.1
AHI during PAP use 4.4±1.7
PAP: positive airway pressure; BMI: body mass index; ESS: Epworth sleepi-
ness scale; PSQI: Pittsburgh sleep quality index; AI: apnea index; AHI:
apnea-hypopnea index; TST: total sleep time; REM: rapid eye movement;
NREM: non-rapid eye movement.
Table 2. Compliance according to hypertension status 
Normal BP (n=11) 5.40±1.22 72.51±22.97 50.02±22.19
HTN (n=12) 5.81±0.99 88.97±16.16 70.21±21.35
P-value 0.121 0.003* 0.062
*P<0.05.
BP: blood pressure; HTN: hypertension; PAP: positive airway pressure.
Percentage
of days on
which PAP
was used
Table 3. Compliance according to PAP mode
APAP: autoadjusting positive airway pressure; CPAP: continuous positive
airway pressure; EPR: expiratory pressure relief.
Percentage
of days on
which PAP
was used
Table 4. Compliance according to nonsupine position sleep time
r -0.210 -0.424 -0.274
P-value 0.325 0.039* 0.195
*P<0.05.
r: Spearman’s Rho correlation coefficient; PAP: positive airway pressure.
Percentage
of days on
which PAP
was used
Mean daily
use (hr)
Percentage
of days on
which PAP was
used for >4 hr
Percentage
of days on
which PAP was
used for >4 hr
Mean daily
use (hr)
Mean daily
use (hr)
Percentage
of days on
which PAP was
used for >4 hr
APAP (n=11) 5.7±1.1 75.1±27.4 61.4±27.2
CPAP (n=10) 5.1±1.4 87.3±12.0 62.2±21.9
EPR (n=3) 5.2±1.4 86.0±20.7 59.2±22.2
P-value 0.572 0.560 0.70994 Clinical and Experimental Otorhinolaryngology  Vol. 2, No. 2: 90-96, June 2009
Compliance according to AHI during PAP use
There was an obvious negative correlation between AHI during
PAP use and percentage of days on which PAP was used for >4
hr (P=0.030, correlation coefficient=-0.443) (Table 5). 
None of age, gender, BMI, neck circumflex, ESS score, PSQI
score, palatine tonsil size, palate position according to Friedman’s
classification, AI score, AHI score, minimum SaO2 (%), apnea-
arousal index score, position dependence of sleep, AHI depen-
dence on REM sleep, PAP pressures (95th percentile pressure,
median pressure, maximal pressure), or air leakage during PAP,
was related to compliance.
In the final stepwise multiple regression analysis showed that
nonsupine sleep time was independently associated with per-
centage of days on which PAP was used (beta=-0.546, P=0.007),
but hypertension was independently associated with percentage
of days on which PAP was used for >4 hr (beta=0.437, P=0.037)
(Table 6).
DISCUSSION
OSAS has been managed with medication, positional therapy,
oral appliances, or upper airway surgery, but PAP is the most
effective treatment (1). Therefore, PAP must be considered the
treatment of choice in patients with moderate-to-severe OSA
(AHI≥15/hr) or in patients with mild OSA (5≤AHI<15/hr)
associated either with symptoms (daytime sleepiness, insomnia,
impaired cognition, mood disorders) or comorbidities (hyper-
tension, previous cerebrovascular accident, ischemic heart dis-
ease) (1, 11, 12).
However, a limitation of PAP therapy is poor compliance and
patients frequently cease therapy. One study reported that only
46% of all CPAP-treated patients with OSA used therapy for at
least 4 hr on at least 70% of all nights (13). Although recent work
has suggested that extensive education and regular feedback can
achieve CPAP compliance rates of 65-89% over 6 months (10),
over 50% of patients commencing on CPAP in the general pop-
ulation may not be using CPAP 1 yr later (14). Also, in the pre-
sent study, 59.4% of PAP-trial patients commenced therapy
but only 34.7% of all PAP-trial patients used devices for more
than 3 months. Lack of education on the benefits and side-effects
of PAP are principally responsible for poor compliance. Thus,
clinicians must educate OSA patients and explain, in full, how
improvements in symptoms and objective sleep variables, and
reductions in risks of comorbidities, may be achieved using PAP.
Furthermore, advisors should emphasize during follow-up that
pressure intolerance during PAP can be solved by changes in
PAP mode, and that discomfort arising from mask use, or nasal
symptoms such as obstruction, congestion, and epistaxis, can be
overcome by optimization of mask design and humidification.
Regular patient observation is necessary.
One method for improving compliance with PAP is the use
of alternative PAP modes. Theoretically, using APAP to deliv-
er the lowest effective pressure might improve PAP acceptance
or compliance. Compliance studies comparing APAP with CPAP
have yielded conflicting results. A study found that use of APAP
did not increase compliance compared to CPAP, but air leakage
was lower and satisfaction higher with APAP (15). A random-
ized study comparing the efficacy of and compliance with APAP
and CPAP reported that both parameters were similar with use
of either modality and there was no correlation between leakage
and compliance (8).
EPR (flexible CPAP) is similar to bilevel PAP in that expira-
tory pressure is reduced, and patient comfort increased, by allow-
ing early expiration pressure to fall below the prescribed PAP,
with a return to the prescribed level at the end of exhalation,
when the need for applied positive-pressure therapy is most crit-
ical (5, 16). A prospective, randomized, crossover study compar-
ed polysomnographic data and compliance in sleep apnea patients
receiving CPAP and flexible CPAP for 7 weeks, and flexible
CPAP was more effective in terms of decreasing AHI, length-
ening device use time, and reducing mouth dryness. Thus, flexi-
ble CPAP was effective in low-compliance patients and in pati-
ents requiring CPAP >9 cm H2O or who experienced dry mouth
using CPAP (17). Another study demonstrated that a change to
flexible PAP improved compliance in patients persistently non-
compliant with CPAP even after standard interventions, includ-
Table 6. Multiple regression analysis with variables associated
with the percentage of days on which PAP used and percentage
of days on which PAP was used for >4 hr*
*Mean daily use (hr) was not included in the multiple regression model.
� P<0.05.
AHI: apnea-hypopnea index; HTN: hypertension; PAP: positive airway pres-
sure.
Percentage of days
on which PAP
was used
Variables
Standardized
P-value
Standardized
P-value
beta coefficient beta coefficient
Table 5. Compliance according to AHI during PAP use
r -0.228 -0.325 -0.443
P-value 0.284 0.121 0.030*
AHI: apnea-hypopnea index; PAP: positive airway pressure; r: Spearman’s
Rho correlation coefficient.
Percentage
of days on
which PAP
was used
Percentage
of days on
which PAP was
used for >4 hr
Percentage of days on
which PAP was
used for >4 hr
Mean daily
use (hr)
Nonsupine sleep time -0.546 0.007
� -0.248 0.232
HTN 0.275 0.151 0.437 0.037*
AHI during PAP use -0.118 0.532 -0.249 0.227
R
2 0.299 0.191ing mask optimization, heated humidification, topical nasal ther-
apy, and sleep apnea education (18).
Our study allowed patients to trial all three modes of APAP,
CPAP, and EPR, and to choose a preferred mode. The use of
manual titration pressure or auto-titration pressure did not affect
the choice of mode. Patients selecting CPAP showed higher auto-
titration pressure levels than manual titration pressure levels, com-
pared with those using APAP. In 24 patients employing PAP for
more than 3 months, preference for APAP was similar to that for
CPAP and there was no difference in compliance by PAP mode.
Consequently, a choice of preferred mode after trialing each mode
may improve patient compliance. 
Studies on factors predicting compliance showed that contin-
uing use of CPAP correlated with higher AHI, higher BMI, high-
er ESS, and greater patient benefit (2, 3). In our study, significant
determinants of PAP use were hypertension, sleep posture, and
lowered AHI with PAP use. None of BMI, AI, AHI, ESS, or other
parameters examined, affected compliance. 
As it is known that long-term CPAP reduces blood pressure in
patients with hypertension and sleep apnea, and that good CPAP
compliance offers significant reduction in blood pressure (19),
patients with hypertension seem to show better compliance with
PAP. We suggest that health concerns may be an important fac-
tor explaining this observation.
During PAP use, patients must wear facial devices, including
nasal, oronasal (full face), or total face masks; nasal prongs; or
pillows. Consequently, longer nonsupine sleep times lower mask
compliance, and PAP use time falls. As AHI fell during PAP use,
symptoms were relieved and use times seemed to increase. Alt-
hough PAP has a high success rate when used to treat sleep ap-
nea, if compliance is only 34.7% as in this study, it is impossible
to state that PAP is more successful than surgery.
The limitation of our study is the imperfect crossover design
in that patients trialed different mode during only a single week,
so we cannot conclude that they will maintain their mode pref-
erence indefinitely. Therefore, we will investigate facial device
details, and side-effects of such devices, and identify solutions for
perceived problems. We will research why patients cease thera-
py, using the ESS and PQSI to measure improvement in subjec-
tive symptoms, and determine how these factors affect compli-
ance. Future studies are needed to assess long-term mode pref-
erence and compliance over 3 yr.
CONCLUSION
In this study, 59.4% of OSA patients with indications for PAP
therapy started using PAP after a trial period and 34.7% of pa-
tients continued to use PAP for more than 3 months. Factors in-
fluencing compliance were hypertension, sleep posture (shorter
nonsupine sleep time), and AHI reduction during PAP use. The
PAP pressure modality selected did not affect mode choice or
compliance.
To improve compliance with PAP, and either a comfortable
mask or changes in sleep posture should be developed. Use of a
preferred mode after trial of each mode is preferable. 
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